文献速递胸部肿瘤

ASP8273对比厄洛替尼或吉非替尼治疗晚期IIIB/IV期非小细胞肺癌的III期随机开放标签研究

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

该全球III期随机开放标签研究纳入530例未经EGFR抑制剂治疗的晚期IIIB/IV期非小细胞肺癌患者,1:1随机接受ASP8273或厄洛替尼/吉非替尼治疗。主要终点无进展生存期两组分别为9.3个月和9.6个月,风险比为1.611(P=0.992)。独立数据监查委员会因ASP8273毒性和有限预测疗效建议终止研究。

要点

  • ASP8273组中位无进展生存期9.3个月,厄洛替尼/吉非替尼组9.6个月,风险比1.611(P=0.992)。
  • ASP8273组客观缓解率33%,厄洛替尼/吉非替尼组47.9%。
  • ASP8273组≥3级治疗中出现的不良事件发生率54.7%,高于厄洛替尼/吉非替尼组的43.5%。

核心结论

  • 一线ASP8273相比厄洛替尼/吉非替尼未显示改善无进展生存期或同等毒性。

研究设计与样本

  • 全球、III期、开放标签、随机研究,比较ASP8273与厄洛替尼/吉非替尼在局部晚期、转移性或不可切除的IIIB/IV期非小细胞肺癌且具有活化EGFR突变患者中的疗效。
  • 患者若曾接受针对转移性疾病的化疗则不符合入选条件。
  • 共530例患者按1:1随机分配至ASP8273组(n=267)或厄洛替尼/吉非替尼组(n=263)。
  • 主要终点为无进展生存期,次要终点包括总生存期、研究者评估的无进展生存期、最佳总缓解率、疾病控制率、缓解持续时间和安全性/耐受性。

主要发现

  • ASP8273组中位无进展生存期为9.3个月(95% CI 5.6-11.1个月),厄洛替尼/吉非替尼组为9.6个月(95% CI 8.8-NE),风险比为1.611(P=0.992)。
  • ASP8273组客观缓解率为33%(95% CI 27.4-39.0),厄洛替尼/吉非替尼组为47.9%(95% CI 41.7-54.1)。
  • 两组中位缓解持续时间相似:ASP8273组9.2个月,厄洛替尼/吉非替尼组9.0个月。
  • ASP8273组发生≥3级治疗中出现的不良事件的患者比例高于厄洛替尼/吉非替尼组(54.7% vs 43.5%)。
  • 独立数据监查委员会进行中期安全性分析后,因ASP8273相对厄洛替尼/吉非替尼的毒性和有限预测疗效建议终止研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 独立数据监查委员会因ASP8273的毒性和相对厄洛替尼/吉非替尼有限的预测疗效建议终止研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI) specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating mutations or EGFR T790M resistance mutations. The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor. PATIENTS AND METHODS: This global, phase III, open-label, randomized study evaluated ASP8273 versus erlotinib/gefitinib in patients with locally advanced, metastatic, or unresectable stage IIIB/IV NSCLC with activating EGFR mutations. They were ineligible if they received prior chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS), and secondary end points included overall survival, investigator-assessed PFS, best overall response rate (ORR), disease control rate, duration of response (DoR), and the safety/tolerability profile. RESULTS: Patients (n = 530) were randomized 1 : 1 to receive ASP8273 (n = 267) or erlotinib/gefitinib (n = 263). Patient demographics between both treatment groups were generally balanced. Median PFS was 9.3 months (95% CI 5.6-11.1 months) for patients receiving ASP8273 and 9.6 months (95% CI 8.8-NE) for the erlotinib/gefitinib group, with a hazard ratio of 1.611 (P = 0.992). The ORR in the ASP8273 group was 33% (95% CI 27.4-39.0) versus 47.9% (95% CI 41.7-54.1) in the erlotinib/gefitinib group. Median DoR was similar for both groups (9.2 months for ASP8273 versus 9.0 months for erlotinib/gefitinib). More grade ≥3 treatment-emergent adverse events (TEAEs) occurred in patients receiving ASP8273 than in those receiving erlotinib/gefitinib (54.7% versus 43.5%). An independent data monitoring committee carried out an interim safety analysis and recommended discontinuing the study due to toxicity and limited predicted efficacy of ASP8273 relative to erlotinib/gefitinib. CONCLUSIONS: First-line ASP8273 did not show improved PFS or equivalent toxicities versus erlotinib/gefitinib. CLINICALTRIAL.GOV NUMBER: NCT02588261.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kelly RJ, Shepherd FA, Krivoshik A, et al. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Ann Oncol. 2019. PMID: 31070709. doi:10.1093/annonc/mdz128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。